Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 1, 2002, Pages 1-19

  Campana, Dario ^a   Coustan Smith, Elaine ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukaemia; Flow cytometry; Minimal residual disease

Indexed keywords

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BLOOD; BONE MARROW; CANCER IMMUNOLOGY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION FUNCTION; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME; ACUTE LYMPHOBLASTIC LEUKEMIA; LEUKEMIA RELAPSE; METHODOLOGY; REVIEW; IMMUNOLOGY; PROGNOSIS; STANDARD;

ANTIBODY; CD10 ANTIBODY; CD19 ANTIBODY; CD22 ANTIBODY; CD33 ANTIBODY; CD34 ANTIBODY; CD38 ANTIBODY; CD45 ANTIBODY; CD5 ANTIBODY; CD58 ANTIBODY; CD66C ANTIBODY; HLA DR ANTIBODY; MONOCLONAL ANTIBODY CD3; NG2 ANTIBODY; UNCLASSIFIED DRUG;

CHILD; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 0036009611     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0182     Document Type: Article

References (74)

1. Childhood acute lymphoblastic leukemia - Current status and future perspective
2. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
3. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
4. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)
5. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia
6. The Medical Research Council's Working Party on Childhood Leukemia. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: Clinical importance and the effect of daunorubicin
7. +) childhood acute lymphoblastic leukemia: Good initial steroid response allows carly prediction of a favorable treatment outcome
8. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
9. Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Children's Cancer Group
10. International Childhood Acute Lymphoblastic Leukaemia Workshop: Sausalito, CA, 30 November-1 December 2000
11. New definition of remission in childhood acute lymphoblastic leukemia
12. Minimal residual disease in leukaemia patients
13. Subpopulations of normal and leukaemic human thymocytes: An analysis with the use of monoclonal antibodies
14. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia
15. The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage
16. Detection of minimal residual disease in acute leukaemia by immunological marker analysis and polymerase chain reaction
17. BIOMED-I concerted action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukaemia (T-ALL)
18. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations
19. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukaemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features
20. +, pre-B, and B cells in bone marrow after allogeneic bone marrow transplantation
21. Terminal deoxynucleotidyl transferase-containing cells in peripheral blood: Implications for the surveillance of patients with lymphoblastic leukaemia or lymphoma in remission
22. Monoclonal antibodies specific to the acute lymphoblastic leukaemi at(1;19)-associated E2A/pbxl chimeric protein: Characterization and diagnostic utility
23. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukaemia blasts from poor-prognosis patients abnormalities of chromosome band 11q23
24. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements
25. Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin
26. A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukaemia cells with high sensitivity
27. The KOR-SA3544 antigen predominantly expressed on the surface of Philadelphia chromosome-positive acute lymphoblastic leukaemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed of human leukaemia cells
28. CD66 expression in acute leukaemia
29. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia
30. Detection of minimal residual disease in acute leukaemia by flow cytometry
31. Flow cytometric analysis of normal B cell differentiation: A frame of reference for the detection of minimal residual disease in precursor-B-ALL
32. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL
33. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukaemia by comparative phenotype mapping: Method and significance
34. Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression
35. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukaemia is associated with chromosomal hyperdiploidy and other favorable prognostic features
36. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations
37. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia
38. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study
39. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer
40. Quantitative analysis of disseminated tumor cells in the bone marrow by automated fluorescence image analysis
41. Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: A follow-up of patients in clinical remission
42. Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukaemia cells in bone marrow
43. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
44. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-I Concerted Leukemia: International Standardization and Clinical Evaluation
45. Detection of rare cells at a frequency of one per million by flow cytometry
46. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7)
47. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia
48. Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias
49. Improved detection of rare CALLA-positive cells in peripheral blood using multiparameter flow cytometry
50. Use of fluorescence threshold triggering and high-speed flow cytometry for rare event detection
51. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis)
52. Lineage switch in acute leukemia
53. Molecular heterogeneity in acute leukaemia lineage switch
54. Analysis of lg and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: Implications for the detection of minimal residual disease by polymerase chain reaction analysis
55. Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse
56. Acute lymphoblastic leukaemia associated antigen. III ALterations in expression during treatment and in relapse
57. Characterization of childhood acute leukaemia with multiple myeloid and lymphoid markers at diagnosis and at relapse
58. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukaemia at diagnosis and relapse: A Pediatric Oncology Group study
59. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia
60. The immunologic detection of minimal residual disease in acute leukemia
61. Flow cytometric determination of atypical antigen expression in acute leukaemia for the study of minimal residual disease
62. Flow cytometric analysis of normal B lymphoid development
63. The detection of residual acute lymphoblastic leukaemia cells with immunologic methods and polymerase chain reaction: A comparative study
64. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
65. Prognostic significance of measuring early clearance of leukaemic cells by flow cytometry in childhood acute lymphoblastic leukemia
66. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
67. Low frequency of TEL-AMLI in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup
68. Cytogenetics of acute lymphoblastic leukaemia in children as a factor in the prediction of long-term survival
69. Prognostic importance of chromosome number in 136 untreated children with acute lymphoblastic leukemia
70. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukaemia of childhood: A Pediatric Oncology Group study
71. Drug therapy: Acute lymphoblastic leukemia
72. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
73. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry
74. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia